Reducing the risk of infection from plasma products: specific preventative strategies

Prevalence of selected developmental disabilities in children 3-10 years of age: the Metropolitan Atlanta Developmental Disabilities Surveillance Program, 1991.

1996 • 835 citations

Detection of a novel DNA virus (TT virus) in blood donors and blood products

1998 • 397 citations

Inactivation of viruses in labile blood derivatives. I. Disruption of lipid‐enveloped viruses by tri(n‐butyl)phosphate detergent combinations

1985 • 324 citations

Inactivation of Transmissible Degenerative Encephalopathy Agents: A Review

2000 • 298 citations

Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt‐Jakob disease in humans

1999 • 293 citations

Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor.

1985 • 258 citations

Feasibility and efficacy of routine PCR screening of blood donations for hepatitis C virus, hepatitis B virus, and HIV-1 in a blood-bank setting

1999 • 257 citations

Infection with hepatitis G virus among recipients of plasma products

1996 • 239 citations

CHEMICAL, CLINICAL, AND IMMUNOLOGICAL STUDIES ON THE PRODUCTS OF HUMAN PLASMA FRACTIONATION. XXXVI. INACTIVATION OF THE VIRUS OF HOMOLOGOUS SERUM HEPATITIS IN SOLUTIONS OF NORMAL HUMAN SERUM ALBUMIN BY MEANS OF HEAT 12

1948 • 171 citations

Surface gene mutants of hepatitis B virus in infants who develop acute or chronic infections despite immunoprophylaxis

1997 • 169 citations

Factor VIII Inhibitors in Previously Treated Haemophilia A Patients with a Double Virus-inactivated Plasma Derived Factor VIII Concentrate

1997 • 168 citations

Inactivation and partition of human T‐cell lymphotrophic virus, type III, during ethanol fractionation of plasma

1986 • 165 citations

New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays

1998 • 149 citations

The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1

1999 • 139 citations

Human Parvovirus B19 and Blood Products

1997 • 122 citations

Hepatitis A virus infections associated with clotting factor concentrate in the United States

1998 • 118 citations

Blood Separation and Plasma Fractionation

1991 • 116 citations

Nanofiltration, a New Specific Virus Elimination Method Applied to High‐Purity Factor IX and Factor XI Concentrates

1994 • 115 citations

Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization

1997 • 114 citations

Studies on the Removal of Abnormal Prion Protein by Processes Used in the Manufacture of Human Plasma Products

2000 • 108 citations

-Propiolactone/Ultraviolet Irradiation: A review of Its Effectiveness for Inactivation of Viruses in Blood Derivatives

1983 • 104 citations

Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study.

1996 • 99 citations

Studies on the Removal of Abnormal Prion Protein by Processes Used in the Manufacture of Human Plasma Products

2000 • 98 citations

A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool

1999 • 97 citations

Virus Inactivation by Solvent/Detergent Treatment and the Manufacture of SD‐Plasma

1998 • 94 citations

Chromatography in plasma fractionation: benefits and future trends

1995 • 93 citations

Hepatitis C Virus Infection Associated With Administration of Intravenous Immune Globulin

1996 • 83 citations

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

1996 • 71 citations

New-variant Creutzfeldt-Jakob disease: the risk of transmission by blood transfusion

1998 • 69 citations

A Novel Method for Removal of Human Immunodeficiency Virus: Filtration with Porous Polymeric Membranes

1989 • 64 citations

Large–Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for Fractionation

2000 • 64 citations

Removal of Viruses from Human Intravenous Immune Globulin by 35 nm Nanofiltration

1998 • 60 citations

TRANSFUSION TRANSMITTED HEPATITIS C AND NON‐A, NON‐B, NON‐C

1994 • 59 citations

Prospective study of hepatitis after factor VIII concentrate exposed to hot vapour

1988 • 56 citations

Inactivation of viruses in labile blood derivatives. II. Physical methods

1985 • 55 citations

Virucidal short wavelength ultraviolet light treatment of plasma and factor VIII concentrate: protection of proteins by antioxidants

1995 • 50 citations

Large‐Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for Fractionation

2000 • 50 citations

Virus Validation of PH 4-treated Human Immunoglobulin Produced by the Cohn Fractionation Process

1998 • 43 citations

Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses

1997 • 42 citations

Virucidal Treatment of Blood Protein Products with UVC Radiation

1997 • 41 citations

Pasteurization of antihemophilic factor and model virus inactivation studies

1985 • 41 citations

Degradation Products of Factor VIII Which Can Lead to Increased Immunogenicity

1999 • 40 citations

Intravenous Immunoglobulins in Clinical Practice

1997 • 39 citations

Inactivation and Partition of Human Immunodeficiency Virus during Kistler and Nitschmann Fractionation of Human Blood Plasma¹

1988 • 39 citations

TT Virus Is Present in a High Frequency of Italian Hemophilic Patients Transfused With Plasma-Derived Clotting Factor Concentrates

1999 • 39 citations

Reduced risk of non‐A, non‐B hepatitis after a first exposure to ‘wet heated’factor VIII concentrate

1987 • 38 citations

Modification of factor VIII in therapeutic concentrates after virus inactivation by solvent-detergent and pasteurisation.

1998 • 38 citations

Virus reduction in the preparation of intravenous immune globulin: in vitro experiments

1999 • 38 citations

Inactivation of HIV, HBV, HCV related viruses and other viruses in human plasma derivatives by pasteurisation.

1993 • 38 citations

Removal of causative agent of Creutzfeldt-Jakob disease(CJD) through membrane filtration method.

1993 • 37 citations

Inactivation of Viruses by Ultraviolet Light1

2015 • 36 citations

Commercial Antithrombin Concentrate Contains Inactive L-forms of Antithrombin

1997 • 36 citations

Efficacy of a high purity, chemically treated and nanofiltered factor IX concentrate for continuous infusion in haemophilia patients undergoing surgery

1999 • 36 citations

Validation of Virus Inactivation and Removal for the Manufacturing Procedure of Two Immunogiobulins and a 5% Serum Protein Solution Treated with β-Propiolactone

1993 • 35 citations

Transfusion-transmissible infections

1998 • 34 citations

Virus Inactivation during Intravenous Immunoglobulin Production

1992 • 33 citations

Improved virus safety and purity of a chromatographically produced Factor IX concentrate by nanofiltration

1995 • 33 citations

Antibody to Hepatitis G Mrus after a Vapour-Heated Factor Vlll Goncentrate

1990 • 32 citations

Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial

1995 • 31 citations

Inactivation of the AIDS‐Causing Retrovirus and Other Human Viruses in Antihemophilic Plasma Protein Preparations by Pasteurization

1986 • 31 citations

Safety aspects in the manufacturing of plasma-derived coagulation factor concentrates

1992 • 30 citations

Transmission of Human Immunodeficiency Virus Type 1 by Dry‐Heated Clotting Factor Concentrates¹

1990 • 30 citations

Virus inactivation in plasma products.

1989 • 30 citations

Inactivation of hepatitis A virus in plasma products by vapor heating

1997 • 29 citations

Transfusion-Transmitted Hepatitis Virus Infection

1995 • 28 citations

Virus removal studies using nanofiltration membranes.

1996 • 28 citations

Inactivation of viruses by β-propiolactone in human cyro poor plasma and IgG concentrates

1998 • 28 citations

Report of EPFA/NIBSC Workshop ‘Nucleic Acid Amplification Tests (NAT) for the Detection of Blood‐Borne Viruses’ Held on 31 October 1996 in Amsterdam, The Netherlands

1997 • 28 citations

Infectious risk of plasma donations: relationship to safety of intravenous immune globulins

1996 • 28 citations

Emerging Viruses in Blood Transfusion

1998 • 27 citations

Virucidal heat‐treatment of single plasma units: a potential approach for developing countries

2000 • 27 citations

Characterisation of a chromatographically produced anti-D immunoglobulin product

1997 • 26 citations

A Pasteurized Therapeutic Plasma

1992 • 26 citations

Transmission of human parvovirus B19 by plasma derived factor VIII concentrates.

1994 • 25 citations

Prospective assessment of donor blood screening for antibody to hepatitis C virus by first- and second-generation assays as a means of preventing posttransfusion hepatitis

1996 • 25 citations

Application of bioaffinity technology in therapeutic extracorporeal plasmapheresis and large-scale fractionation of human plasma

1998 • 24 citations

EMERGING ISSUES IN BLOOD SAFETY

1998 • 23 citations

Prevalence of TT virus in plasma pools and blood products

1999 • 21 citations

Strategies for viral inactivation

1995 • 21 citations

Possible association between serum GB virus C RNA level and disease activity in fulminant hepatitis type G

1999 • 21 citations

A Cross-over Pharmacokinetic Study of a Double Viral Inactivated Factor IX Concentrate (15 nm Filtration and SD) Compared to a SD Factor IX Concentrate

1998 • 20 citations

Current safety of clotting factor concentrates.

1990 • 19 citations

Prions: Properties, Occurrence, Modes of Transmission and Relevance for Blood Transfusion and Blood Derivatives

1998 • 18 citations

Genomic Screening for Blood‐Borne Viruses in Transfusion Settings

1998 • 17 citations

AN OUTBREAK OF TYPE B HEPATITIS ASSOCIATED WITH TRANSFUSION OF PLASMA PROTEIN FRACTION

1976 • 17 citations

Microparticle Removability of the Regenerated Cellulose Hollow Fiber (BMM): An Electron Microscopic Evaluation

1991 • 16 citations

Chromatographic removal of viruses from plasma derivatives.

1993 • 16 citations

Screening for HBV, HCV and HIV genomes in blood donations: shortcomings of pooling revealed by a multicentre study simulating real-time testing

1999 • 16 citations

Transmission of hepatitis G virus in patients with angioedema treated with steam‐heated plasma concentrates of C1 inhibitor

1998 • 16 citations

Transfusion virology: progress and challenges

1998 • 15 citations

Prevention of Infections Transmissible by Blood Derivatives

1998 • 14 citations

Surveillance for Bloodborne Infections

1999 • 14 citations

Viral safety of a new highly purified factor VIII (OCTATE)

1996 • 14 citations

Strategies to Produce Virus-Safe Blood Derivatives

2015 • 13 citations

PCR testing of plasma pools: From concept to reality

1999 • 13 citations

Large-scale preparation of highly purified human C1-inhibitor for therapeutic use.

1994 • 13 citations

Prevalance of hepatitis C virus in plasma pools and the effectiveness of cold ethanol fractionation

1996 • 11 citations

Removal of abnormal prion protein by plasma fractionation

2000 • 11 citations

Serum and serum substitutes: virus safety by inactivation or removal.

1999 • 11 citations

Potential deferral criteria predictive of human immunodeficiency virus positivity among blood donors in Thailand

1994 • 10 citations

Partitioning and inactivation of viruses during isolation of albumin and immunoglobulins by cold ethanol fractionation.

1993 • 10 citations

Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial*1

1995 • 9 citations

Viral validation design of a manufacturing process.

1999 • 9 citations

Viral inactivation vs biological activity.

1993 • 8 citations

Sensitivity of PCR Assays for the Determination of Hepatitis A Virus RNA in Plasma Pools

1999 • 7 citations

Removal and Inactivation of Hepatitis B Virus from Contaminated Pooled Plasma in a Large–Scale Manufacturing Process for Factor VIII and Human Serum Albumin

1999 • 6 citations

SAFETY OF RECOMBINANT AND PLASMA-DERIVED MEDICINALS FOR THE TREATMENT OF COAGULOPATHIES

2000 • 6 citations

Viral safety of plasma-derived factor VIII and IX concentrates.

1997 • 6 citations

Prevalence of GB Virus C/Hepatitis G Virus Ribonucleic Acid and Anti-Hepatitis G Virus-E2 Antibodies among Japanese Children with Histories of Transfusions or with Liver Diseases

1999 • 5 citations

Good manufacturing practice (GMP) compliance in the biologics sector: plasma fractionation

1999 • 5 citations

[Nanofiltration in production of Beriplex P/N: increasing the capacity of virus elimination while maintaining product quality].

1996 • 5 citations

Strategy of Virus Removal / Inactivation of Plasma-Derived Products : Interest of Nanofiltration as a New Virus Elimination Method

1994 • 5 citations

Removal and Inactivation of Hepatitis B Virus from Contaminated Pooled Plasma in a Large-Scale Manufacturing Process for Factor VIII and Human Serum Albumin

1999 • 4 citations

Pasteurisation induced changes in an antithrombin iii concentrate

1986 • 4 citations

Virus inactivation and prevalence of GBV‐C in haemophiliacs

1997 • 3 citations

Research and Development Commitments in an Integrated Plasma Collection and Plasma Fractionation Environment

1998 • 3 citations

Cited By (0)

Loading...